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Vitamin B6 is a water-soluble vitamin, and is readily metabolized and excreted, so it has
generally been assumed to have negligible toxicity, although at very high levels of intake it can
cause peripheral nerve damage. Nutritional deficiency disease is extremely rare, although a
significant proportion of the population shows biochemical evidence of inadequate status, despite
apparently adequate levels of intake. The vitamin has been used to treat a wide variety of
conditions, which may or may not be related to inadequate intake. In some conditions use of
vitamin B6 supplements has been purely empirical; in other conditions there is a reasonable
physiological or metabolic mechanism to explain why supplements of the vitamin many times
greater than average requirements may have therapeutic uses. However, even in such conditions
there is little evidence of efficacy from properly conducted controlled trials.
Vitamin B6: Carpal tunnel syndrome: Glucose tolerance: Premenstrual syndrome
In June 1997 the UK Department of Health Committee on
Toxicity proposed limits on the amounts of vitamin B6 that
may be supplied in supplements (Department of Health,
1997). The proposals can be interpreted as an attempt to
differentiate between levels of intake that may be consid-
ered to be nutritionally relevant and higher levels that can be
considered to be for pharmaceutical purposes, to treat a
disease or condition:
(1) up to 10 mg may be sold freely as a nutritional supple-
ment (this is some 6-fold higher than the reference
nutrient intake (RNI), although the value was derived
by extrapolation from toxicological data);
(2) 10–50 mg/d may only be sold in a pharmacy, where
professional advice is assumed to be available;
(3) over 50 mg/d may only be provided on prescription, since
at or above this level of intake there is considered to be a
risk of adverse effects, which therefore have to be balanced
against the benefits in treating a clinical condition.
The proposals generated very considerable controversy,
with arguments both from those who opposed all regulation
of nutritional supplements and those who did not oppose
regulation, but questioned the scientific evidence on which
the limits had been established. In July 1998 the proposed
legislation was put in abeyance, pending further examina-
tion of the evidence concerning toxicity of the vitamin.
Regardless of arguments concerning the safety of high
intakes of vitamin B6, there is a need to consider the
evidence for efficacy of the vitamin in treating the variety
of conditions for which it is widely recommended, often at
intakes of up to 250–500 mg/d (compared with the RNI of
1 × 2–1 × 5 mg/d). The aim of the present review is to examine
the evidence for the efficacy of vitamin B6 supplements in
treating a variety of conditions.
Metabolism and metabolic functions of vitamin B6
Six vitamers have vitamin B6 metabolic activity: pyridox-
ine, pyridoxal and pyridoxamine, and their 59-phosphates.
The metabolically active coenzyme is pyridoxal 59-phos-
phate (PLP). In the liver there is rapid oxidation of the other
vitamers to pyridoxal, and rapid phosphorylation to PLP,
which is the main circulating vitamer exported from the
liver bound to albumin. Uptake into peripheral tissues is by
extracellular dephosphorylation, followed by metabolic
trapping intracellularly as PLP. PLP that is not bound to
enzymes is rapidly dephosphorylated, and surplus pyridoxal
in tissues is oxidized to pyridoxic acid, which is the main
urinary metabolite of the vitamin.
In amino acid metabolism PLP reacts with the a-amino
group of the substrate; reactions of PLP-dependent enzymes
include:
(a) decarboxylation of amino acids to yield amines, which are
neurotransmitters or hormones, e.g. g-aminobutyrate,
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histamine, noradrenaline (and hence adrenaline),
serotonin;
(b) transamination of amino acids to yield their keto-acids
(oxo-acids), which are then oxidized as metabolic fuels;
(c) a variety of reactions involving the side-chains of amino
acids, including kynureninase (EC 3.7.1.3), cystathio-
nine synthetase (EC 4.2.1.22) and cystathionase (EC
4.4.1.1);
(d) decarboxylation of phosphatidylserine to phosphatidyl-
ethanolamine in phospholipid synthesis.
In glycogen phosphorylase (EC 2.4.1.1) PLP acts as a
phosphate buffer at the active site of the enzyme (Palm et al.
1990). Before this catalytic role was established, it was
assumed that muscle acted as a storage pool of vitamin B6;
however, PLP is not released from muscle in times of
deficiency, although it is released in prolonged fasting,
when glycogen reserves are depleted, and there is an
increased requirement for PLP in the liver for transamina-
tion of amino acids for gluconeogenesis (Black et al. 1977,
1978).
PLP also acts to terminate the actions of steroid and other
nuclear-acting hormones, including vitamins A and D and
thyroid hormone. It binds to a lysine residue in the hormone
receptor protein, displacing it from binding to the hormone-
response element on DNA, and so ending the enhancement
of gene expression. Studies in experimental animals have
shown that various steroid hormones are accumulated in the
nucleus of target tissues to a greater extent, and for longer,
in vitamin B6 deficiency, with some evidence of enhanced
end-organ responsiveness to low doses of hormones (Symes
et al. 1984; Bowden et al. 1986; Bender, 1987). Studies with
cells in culture have shown that acute vitamin B6 depletion
(addition of the antimetabolite 4-deoxypyridoxine) leads to
a twofold increase in hormone-stimulated rate of expression
of genes with a variety of hormone-response elements, and
conversely, addition of high concentrations of pyridoxal to
the culture medium results in a halving of the rate of gene
expression in response to the hormones (Allgood et al.
1990; Allgood & Cidlowski, 1992; Tully et al. 1994).
Maksymowych et al. (1993) reported that pyridoxal had a
cytotoxic effect towards melanoma cells in culture, prevent-
ing glucocorticoid action. Administration of vitamin B6 has
been demonstrated to prevent the development of fetal
abnormalities induced in experimental animals by the vita-
min A analogue, etretinate (Jacobsson & Granstrom, 1996),
and Key et al. (1997) reported a potential protective effect
of vitamin B6 against prostate cancer, presumably due to
attenuation of steroid hormone responsiveness of target
tissues.
Requirements and reference nutrient intakes
Clinical deficiency of vitamin B6 is more or less unknown;
the only reported cases were in the early 1950s, associated
with infant milk formula that had been severely overheated
in manufacture, leading to the formation of pyridoxyllysine
by reaction between the vitamin and the e-amino groups of
lysine in protein (Coursin, 1954). Not only is pyridoxylly-
sine nutritionally unavailable as a source of the vitamin, but
it also has antivitamin activity (Gregory, 1980a,b).
Estimates of requirements and RNI are based on
depletion–repletion studies in which either the plasma
concentration of the vitamin or the ability to metabolize a
test dose of tryptophan or methionine was used as the index
of adequacy (Miller & Linkswiler, 1967; Kelsay et al.
1968a,b; Canham et al. 1969). Coburn (1996) has shown
that although some 70–80 % of total body vitamin B6 is
associated with muscle glycogen phosphorylase, this pool
has a slow turnover; the remaining 20–30 % of the body
pool, largely associated with amino acid metabolism (and
steroid hormone action), has a more rapid turnover. There-
fore it is likely that protein intake, or the burden of amino
acids to be metabolized, will have a significant effect on
vitamin B6 requirements. Certainly the depletion–repletion
studies of Miller & Linkswiler (1967), Kelsay et al.
(1968a,b) and Canham et al. (1969) demonstrated that
biochemical evidence of depletion developed more rapidly
during depletion in subjects fed on a high-protein diet, while
repletion required a higher intake of the vitamin than in
subjects fed on a low-protein diet. Current RNI are calcu-
lated on the basis of 15 mg vitamin B6 /g protein intake
(Department of Health, 1991).
Average intakes of vitamin B6 in Britain are significantly
above the RNI, and even people in the lowest 2 × 5 centile
meet the RNI (Gregory et al. 1990). However, several
studies show that a significant proportion of adults have
biochemical evidence of inadequate vitamin B6 nutrition by
one or other of the two criteria most commonly used:
plasma concentration of PLP or erythrocyte transaminase
activation coefficient (see Table 1). This suggests that
current estimates of vitamin B6 requirements may be too
low, although there is little evidence that marginal plasma
concentrations of PLP or marginally elevated transaminase
activation coefficients have any functional significance.
Kretsch et al. (1995) and Hansen et al. (1996) have
investigated a number of markers of status in vitamin B6
depletion–repletion studies in women; both studies suggest
that the requirement to meet the most sensitive criteria of
adequacy indicates an RNI of 20 mg/g protein. It is not clear
whether this represents a sex difference (most of the earlier
studies were performed on men) or whether the more
recent studies were more sensitive in detecting marginal
inadequacy.
Potential benefits of higher levels of intake:
homocysteine metabolism
The identification of hyperhomocysteinaemia as an inde-
pendent risk factor in atherosclerosis and CHD (Verhoef &
Stampfer, 1995; Boers, 1997; D’Angelo & Selhub, 1997)
has led to suggestions that intakes of vitamin B6 higher than
are currently considered adequate to meet requirements may
be desirable. Homocysteine is an intermediate in methio-
nine metabolism, and may undergo one of two metabolic
fates, as shown in Fig. 1: remethylation to methionine (a
reaction that is dependent on vitamin B12 and folic acid), or
onward metabolism leading to the synthesis of cysteine
(trans-sulfuration).
The trans-sulfuration pathway has two PLP-dependent
enzymes: cystathionine synthetase and cystathionase, and
forms the basis of the methionine load test for vitamin B6
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status: measurement of homocysteine in plasma or urine
after a test dose of methionine (Linkswiler, 1981). It has
been considered to be less subject to artifacts and false
positive results than the tryptophan load test (Bender &
Wynick, 1981).
Selhub et al. (1993) reported measurements of plasma
homocysteine and vitamin B6 and folate status in 1160
elderly survivors (aged 67–96 years) of the Framingham
study cohort. Hyperhomocysteinaemia was most signifi-
cantly correlated with low folate status, but there was also
a significant association with low vitamin B6 status. Results
from the Nurses’ Health Study (Rimm et al. 1998) showed
that cardiovascular disease risk was lowest among those
women with the highest intakes of folate and vitamin B6.
Since the sources of both folate and vitamin B6 in those
people with the highest intakes were fortified breakfast
cereals and multivitamin supplements, the authors con-
cluded that it was not possible to distinguish between
potential protective effects of the two vitamins.
Ubbinck and coworkers (Ubbinck et al. 1994; Ubbinck,
1997) showed that while folate supplements lowered fasting
homocysteine levels in moderately hyperhomocysteinaemic
subjects, 10 mg vitamin B6 /d had no effect. Dierkes et al.
(1998) similarly showed that while folate supplements
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Table 1. Evidence of inadequate vitamin B6 nutritional status in developed countries
n % Deficient Criterion Reference
Breast-fed infants 84 10 Pyridoxal phosphate Wilson & Davies (1984)
Preschool children 35 9 Pyridoxal phosphate Fries et al. (1981)
Young women embarking on contraceptive study 129 0× 8 Pyridoxal phosphate Bender (1993)
Young women embarking on contraceptive study 129 13× 2 Aspartate transaminase activation Bender (1993)
Adolescent girls 127 13 Alanine transaminase activation Kirksey et al. (1978)
Pregnant adolescents 122 17 Alanine transaminase activation Martner-Hawes et al. (1986)
Low-income pregnant women 127 68 Alanine transaminase activation Schuster et al. (1981)
Pregnant women 458 42 Aspartate transaminase activation Heller et al. (1973)
Hospital patients 650 25 Aspartate transaminase activation Lemoine et al. (1980)
Free-living elderly subjects 198 27 Pyridoxal phosphate Schrijver et al. (1987)
Free-living elderly subjects 198 26 Aspartate transaminase activation Schrijver et al. (1987)
Elderly men undergoing prostate surgery 94 4× 3 Pyridoxal phosphate Bender (1993)
Elderly men undergoing prostate surgery 94 8× 5 Aspartate transaminase activation Bender (1993)
Hospitalized elderly subjects 153 19 Aspartate transaminase activation Hoorn et al. (1975)
Hospitalized elderly subjects 102 28 Alanine transaminase activation Vir & Love (1978)
Men, various ages 617 25 Pyridoxal phosphate Rose et al. (1976)
Fig. 1. Methionine metabolism. Methionine synthetase, EC 2.1.1.13; methionine
adenosyltransferase, EC 2.5.1.6; cystathionine synthetase, EC 4.2.1.22; cystathionase,
EC 4.4.1.1.
reduced plasma homocysteine levels in people who were not
hyperhomocystinaemic, vitamin B6 supplements had no
effect. In Ubbinck’s studies, vitamin B6 supplements did
reduce the peak plasma concentration of homocysteine
following a test dose of methionine. This can probably be
explained on the basis of the kinetics of the enzymes
involved; the Km of cystathionine synthetase is 10-fold
higher than that of methionine synthetase (EC 2.1.1.13).
Under basal conditions, little homocysteine is metabolized
by way of the trans-sulfuration pathway; it is only after a
loading dose of methionine, when homocysteine rises to
high levels, that the activity of cystathionine synthetase,
rather than the concentration of its substrate, is limiting.
Thus it seems unlikely that intakes of vitamin B6 greater
than amounts that are adequate to prevent metabolic signs of
deficiency will be beneficial in lowering plasma concentra-
tions of homocysteine. This conclusion is supported by a
meta-analysis of intervention studies which demonstrated
no effect of vitamin B6 supplements on plasma homo-
cysteine (Homocysteine Lowering Trialists’ Collaboration,
1998).
Pharmacological uses of vitamin B6
A number of (rare) genetic conditions are known in which a
PLP-dependent enzyme has a defect in the coenzyme
binding site, and only has significant activity when the
tissue concentration of PLP is very much higher than
normal. For such conditions (listed in Table 2), supplements
of 200–1000 mg/d are required for life (Frimpter et al. 1969;
Mudd, 1971; Fowler, 1985).
Vitamin B6 has been reported to be effective in suppression
of lactation (Marcus, 1975; Gupta & Sharma, 1990), although
other reports have shown no difference from placebo (Mac-
donald et al. 1976). Because the vitamin suppresses the
increase in prolactin induced by treatment with the dopamine
receptor antagonist pimozide, and because lactation is also
suppressed by the dopamine agonist bromocriptine (Boes,
1980), it has been suggested that it acts to stimulate dopami-
nergic activity in the hypothalamus (Delitala et al. 1977).
However, it is more likely that its action is by reduction in
target tissue responsiveness to steroid hormones that stimulate
prolactin secretion.
Supplements of vitamin B6 ranging from 25 to 500 mg/d
have been recommended for treatment of a variety of
conditions, discussed later, in which there is an underlying
physiological or biochemical mechanism to justify the use
of supplements, although in most cases there is little
evidence of efficacy. It has also been used empirically,
with little or no evidence of efficacy, in the treatment of a
variety of conditions, including: acute alcohol intoxication
(Mardel et al. 1994), atopic dermatitis (Mabin et al. 1995),
autism (Rimland et al. 1978; Rimland, 1988; Lelord et al.
1982; Pfeiffer et al. 1995; Findling et al. 1997), dental caries
(Hillman, 1964), diabetic peripheral neuropathy (Levin et al.
1981; Cohen et al. 1984), Down’s syndrome (Pueschel et al.
1980; Coleman et al. 1985), Huntington’s chorea (Barr
et al. 1978), schizophrenia (Bucci, 1973), and steroid-
dependent asthma (Sur et al. 1993).
Side-effects of oral contraceptives
The high-dose oral contraceptives of the 1960s had a variety
of side-effects, including depression of mood and impaired
glucose tolerance. A number of studies showed that supple-
ments of 100 mg vitamin B6 /d relieved the depression and
normalized glucose tolerance in women taking contracep-
tives (Benninck & Schreurs, 1975; Adams et al. 1976;
Spellacy et al. 1977). Villegas-Salas et al. (1997) showed
that the side-effects of low-dose combined oral contracep-
tives, such as nausea, vomiting, dizziness, depression and
irritability, showed no greater response to 150 mg vitamin
B6 /d than to placebo.
Rose (1966a,b) was the first to report apparent vitamin
B6 deficiency in women taking high-dose oestrogen–
progestagen contraceptives. He reported impaired meta-
bolism of tryptophan with increased urinary excretion of
xanthurenic and kynurenic acids after a test dose of the
amino acid (see Fig. 2). Since then there have been many
reports of abnormal tryptophan metabolism in women
taking both oral contraceptives and menopausal hormone
replacement therapy, which have generally been interpreted
as indicating oestrogen-induced vitamin B6 deficiency or
depletion.
In many cases tryptophan metabolism has been normal-
ized by supplements of 20–50 mg vitamin B6 /d, but not by
nutritionally relevant amounts. Furthermore, when indices
of vitamin B6 status other than tryptophan metabolism have
been assessed (e.g. the metabolism of a test dose of
methionine, plasma concentrations of B6 vitamers or the
activation of erythrocyte transaminases by PLP added in
vitro), these have been normal, suggesting that the impair-
ment of tryptophan metabolism may be due to an effect
other than vitamin B6 depletion.
One explanation of the beneficial effect of vitamin B6
supplements on tryptophan metabolism in women taking
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Table 2. Vitamin B6-responsive inborn errors of metabolism
Enzyme affected EC number
Convulsions of the newborn Glutamate decarboxylase (# GABA synthesis) 4.1.1.15
Cystathioninuria Cystathionase (see Fig. 1) 4.4.1.1
Gyrate atrophy with ornithinuria Orninthine-d-aminotransferase 2.6.1.13
Homocystinuria Cystathionine synthetase (see Fig. 1) 4.2.1.22
Primary hyperoxaluria, type 1 Peroxisomal alanine-glyoxylate transaminase 2.6.1.44
Sideroblastic anaemia d-Aminolevulinate synthase (# haem synthesis) 2.3.1.37
Xanthurenic aciduria Kynureninase (see Fig. 2) 3.7.1.3
GABA, g-aminobutyric acid; #, reduced.
oestrogens, and indeed of the extreme sensitivity of trypto-
phan metabolism as an index of vitamin B6 status, may lie in
the enzymology of kynureninase. In common with a number
of other PLP-dependent enzymes, kynureninase catalyses
not only its normal reaction (cleavage of the b-C–g-C bond
of the substrate, releasing alanine and hydroxyanthranilic
acid), but also, slowly, cleavage of the a-C–amino bond, the
half-reaction of transamination (Meister, 1990). This results
in formation of pyridoxamine phosphate at the active site of
the enzyme, and loss of activity. The enzyme can only be
reactivated if there is a sufficiently high concentration of
PLP to displace pyridoxamine from the catalytic site and
reform the active holo-enzyme. Normally there is a con-
siderable amount of catalytically inactive kynureninase in
the liver, which is activated by addition of PLP in vitro; this
may be either true apo-enzyme or enzyme that has been
inactivated by transamination.
Another factor which may account for the reduction in
excretion of tryptophan metabolites after a test dose in
people receiving relatively high supplements of vitamin
B6 is the effect of PLP on enzyme induction by steroid
hormones. The rate of entry of tryptophan into the oxidative
pathway is limited by the activity of tryptophan dioxygenase
(EC 1.13.11.11), which is induced by glucocorticoid hor-
mones; high intakes of vitamin B6 would be expected to
reduce synthesis of the enzyme by terminating hormone
action, so reducing metabolic flux through the pathway.
It was noted earlier that there is little evidence that
oestrogens cause vitamin B6 deficiency or depletion, and
although the metabolism of a test dose of tryptophan is
abnormal, other indices of vitamin B6 status are not. Bender
& Wynick (1981) showed that oestrogen metabolites are
competitive inhibitors of kynureninase, and will impair
tryptophan metabolism, leading to results of a tryptophan
load test similar to those seen in vitamin B6 deficiency, but
by a different mechanism. They concluded that the trypto-
phan load test was not a useful indicator of vitamin B6
status for use in field studies, although it is still useful in
experimental depletion–repletion studies to determine
requirements.
Impaired glucose tolerance and diabetes mellitus
Wynn & Doar (1966) reported impaired glucose tolerance in
18 % of women taking (high-dose) oral contraceptives,
which returned to normal on withdrawal of the steroids.
Impaired glucose tolerance is also common in pregnancy,
and may be severe enough to be classified as diabetes
mellitus, so-called gestational diabetes, which usually
resolves on parturition. In women taking oral contraceptives
and in gestational diabetes, several studies have shown that
supplements of about 100 mg vitamin B6 /d result in
improved glucose tolerance (Benninck & Schreurs, 1975;
Adams et al. 1976; Spellacy et al. 1977). Rose et al. (1975)
reported that vitamin B6 deficiency impaired glucose toler-
ance in women taking oral contraceptive steroids, but not in
control women, and the abnormality was corrected by
vitamin B6 supplements.
There are derangements of tryptophan metabolism in
pregnancy. As discussed earlier, oestrogen metabolites
inhibit kynureninase, and Bender & Totoe (1984a)
showed that oestrogens lead to reduced activity of kynur-
enine hydroxylase (EC 1.14.13.9) and hydroxyanthranilate
oxidase (EC 1.13.11.6) although the mechanism is unclear.
In animals, Van-de-Kamp & Smolen (1995) showed that
pregnancy has effects on tryptophan metabolism that are
additive to those seen in vitamin B6 deficiency, and that are
resistant to modest supplements of the vitamin. As a result,
in pregnancy or in response to (high-dose) oral contra-
ceptives, tissue concentrations of kynurenine, hydroxy-
kynurenine and xanthurenic and kynurenic acids are
higher than normal.
Kotake et al. (1975) suggested that the impairment of
glucose tolerance was associated with high plasma concen-
trations of xanthurenic acid, which forms a biologically
inactive complex with insulin. The improvement following
high doses of vitamin B6 could then be explained by
activation of apo-kynureninase or reactivation of kynureni-
nase that had been inactivated as a result of transamination.
However, Cornish & Tesorio (1975) were unable to demon-
strate any effect of xanthurenic acid administration on
glucose tolerance in rats. Adams et al. (1976) suggested
that the effect of vitamin B6 on glucose tolerance in women
taking oral contraceptives was due to increased formation
of quinolinic acid as a result of relief of the impairment
of kynureninase activity; quinolinic acid is an inhibitor of
phosphoenolpyruvate carboxykinase (EC 4.2.2.31), one of
the key enzymes of gluconeogenesis. They demonstrated an
improvement in glucose tolerance in response to tryptophan
to increase the synthesis of quinolinic acid.
An alternative explanation of impaired glucose tolerance
in the presence of tryptophan metabolites that would be
reduced by high doses of vitamin B6 has been proposed by
Noto & Okamoto (1978). They reported that xanthurenic
and kynurenic acids inhibit the synthesis of pro-insulin in
isolated pancreatic islets, and hydroxykynurenine inhibits
the secretion of insulin, a finding confirmed by Rogers &
Evangelista (1985).
Spellacy et al. (1977) reported improved glucose toler-
ance in thirteen women with gestational diabetes in response
to supplements of 100 mg vitamin B6 /d. However, Gillmer
& Mazibuko (1979) reported that while a similar supple-
ment normalized urinary excretion of xanthurenic acid in
women with gestational diabetes, it resulted in improved
glucose tolerance in only two of their thirteen subjects, and
led to more impaired glucose tolerance in six subjects.
There are conflicting results on the effects of vitamin B6
status on glucose tolerance. Rao et al. (1980) reported no
effect of marginal vitamin B6 status on glucose tolerance or
insulin secretion in response to a glucose load in people with
non-insulin-dependent diabetes. Rao (1983) reported that in
a group of non-diabetic subjects with marginal vitamin B6
status glucose tolerance was in fact better than in those with
adequate status. The response of plasma insulin to the
glucose load was normal, suggesting enhanced sensitivity
to the hypoglycaemic action of insulin in marginal vitamin
B6 deficiency. Toyata et al. (1981) reported that in insolated
pancreatic islets from vitamin B6 deficient rats there was
impaired secretion of insulin, and plasma insulin was sig-
nificantly lower than normal in the deficient rats in response
to a glucose load. Rao & Mohan (1982) reported low plasma
concentrations of insulin in vitamin B6-deficient rats.
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There is some evidence that PLP may be beneficial in
overcoming some of the effects of poor glycaemic control in
diabetes. Hayakawa & Shibata (1991) reported that in vitro
PLP inhibited the non-enzymic reaction between lysine and
glucose (the Maillard reaction). They also showed that
administration of PLP to genetically diabetic mice reduced
the thickening of the glomerular basement membrane,
which has been attributed to non-enzymic glycation of
connective tissue proteins. Solomon & Cohen (1989)
showed that supplements of 150 mg vitamin B6 /d led to a
significant reduction in glycated haemoglobin in men with
non-insulin-dependent diabetes, and hence improved O2
transport capacity, although there was no change in glycae-
mic control. While these results suggest beneficial effects of
vitamin B6 supplementation in diabetes, the reduced glyca-
tion of proteins is due to reaction between PLP and the
amino groups that would otherwise be glycated. Ganea &
Harding (1996) reported that PLP did indeed decrease the
binding of glucose and galactose to lens proteins, but bound
itself, causing changes in the absorbance and fluorescence
spectra, and inducing aggregation of the proteins.
Overall there is little convincing evidence either that
vitamin B6 supplements will be of any use in the treatment
of diabetes (possibly apart from gestational diabetes), or that
vitamin B6 deficiency is a significant factor in the develop-
ment of diabetes.
Depression
There is a great deal of evidence that deficiency of serotonin
(5-hydroxytryptamine) or the catecholamines (dopamine,
noradrenaline and adrenaline) is a factor in depressive
illness (Ashcroft et al. 1972), and many antidepressant
drugs act to decrease the catabolism of amines or enhance
their interaction with receptors. A key enzyme involved in
the synthesis of serotonin and the catecholamines is aro-
matic amino acid decarboxylase (EC 4.1.1.28), which is
PLP-dependent. Therefore, it has been suggested that vita-
min B6 deficiency may result in reduced formation of the
neurotransmitters, and so be a factor in the aetiology of
depression. Conversely, it has been suggested that supple-
ments of vitamin B6 may increase aromatic amino acid
decarboxylase activity, and so increase amine synthesis and
have a mood-elevating or antidepress-ant effect.
There is little evidence that vitamin B6 deficiency affects
the activity of aromatic amino acid decarboxylase (Eberle &
Eiduson, 1968; Eiduson et al. 1972). Perry et al. (1985)
reported that in patients with kidney failure, undergoing
dialysis, the brain concentration of PLP fell to about 50 % of
normal, with no effect on serotonin, catecholamines or their
metabolites. However, like kynureninase, aromatic amino
acid decarboxylase can undergo self-inactivation by cata-
lysing transamination (Meister, 1990), and it is likely that at
times of low availability of PLP, reactivation of the enzyme
may be impaired.
Dakshinamurti et al. (1976) reported a low brain con-
centration of serotonin, but not catecholamines, in vitamin
B6-deficient rats, and Siow & Dakshinamurti (1985)
reported reduced decarboxylase activity towards 5-hydroxy-
tryptophan, but not dopa (3-hydroxytyrosine), in the brains
of vitamin B6-deficient animals. The decarboxylase
undergoes mechanism-dependent inactivation in the pre-
sence of serotonin, and may thus be more susceptible to
inactivation in serotoninergic neurones than in catechola-
minergic neurones. It is unlikely that this explains the
differential effect of vitamin B6 deficiency on serotonin
and catecholamine formation, since the inactivation is the
result of a covalent modification of the catalytic site, not the
coenzyme, and is not reversed by incubation with PLP
(Bertoldi et al. 1996).
Bender & Totoe (1984b) showed that in rats high doses of
vitamin B6 (10 mg/kg body weight) led to decreased oxida-
tive metabolism of tryptophan, an increased plasma con-
centration of tryptophan, and increased uptake of tryptophan
into the brain, leading to an increased rate of serotonin
turnover. They suggested that vitamin B6 supplements
might be a useful adjunct to tryptophan for the treatment
of depression. It is likely that the impairment of tryptophan
oxidation was the result of reduced induction of tryptophan
dioxygenase by glucocorticoid hormones in the presence of
high concentrations of PLP.
Overall, however, there is little or no evidence from
clinical trials that vitamin B6 is effective in the treatment
of depressive illness.
The premenstrual syndrome
The studies showing that vitamin B6 supplements were
effective in overcoming some of the side-effects of (high-
dose) oral contraceptives have led to the use of vitamin B6 in
treatment of the premenstrual syndrome, the condition of
nervousness, irritability, emotional disturbance, headache
and/or depression suffered by many women for up to 10 d
before menstruation. There is no evidence that women who
suffer from premenstrual syndrome have any lower vitamin
B6 status than do others (Ritchie & Singkamani, 1986; van
den Berg et al. 1986; Mira et al. 1988), and the doses used
have been in the region of 50–200 mg/d, which is very much
higher than would be required to correct any deficiency of
the vitamin.
Kleijnen et al. (1990) reviewed twelve placebo-con-
trolled double-blind trials of vitamin B6 in the premenstrual
syndrome and concluded that the evidence for beneficial
effects was weak. In three of the studies cited there was a
significant beneficial effect of vitamin B6 supplements:
Abraham & Hargrove (1980) used a dose of 500 mg/d,
Hallman & Oreland (1987) 300 mg/d and Barr (1984)
100 mg/d. A further five studies yielded ambiguous results.
Doll et al. (1989) reported a significant beneficial effect of
50 mg/d on depression, irritability and tiredness, but none of
the other premenstrual symptoms. Kendall & Schnurr
(1987) reported that 150 mg/d led to some improvement in
dizziness, vomiting and behavioural changes, but consider-
able physical and affective symptoms remained. Williams et
al. (1985) showed an improvement for 82 % of subjects
receiving 100 mg vitamin B6 /d, and 70 % of those receiving
placebo. Smallwood et al. (1986) reported a positive trend
but no statistical significance using 200 mg/d, and Stokes &
Mendels (1972) reported disappointing and ‘not clear’
results using 50 mg/d. The remaining four studies they
reviewed reported no beneficial effects of doses of between
100 and 500 mg/d.
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Hagen et al. (1985) found no significant difference
between vitamin B6 (100 mg/d) and placebo, but reported
that whichever treatment was used second in their double-
blind cross-over trial was significantly better than the
treatment used first.
Despite the lack of evidence of efficacy, the major use of
vitamin B6 supplements, either prescribed or self-pre-
scribed, is in the treatment of premenstrual syndrome.
Morning sickness
Doses of vitamin B6 of between 50 and 200 mg have an anti-
emetic effect, and the vitamin has been used to overcome
the nausea associated with radiotherapy. It was also been
used, empirically, since the 1940s to treat morning sickness
in pregnancy. It was included together with doxylamine
succinate in Bendectin (Debendox), which was prescribed
for treatment of morning sickness, and later withdrawn on
suspicion of teratogenicity. Brent (1995) concluded that
there was no evidence of teratogenic effects of the combined
formulation.
There is no evidence that women who suffer from severe
nausea and vomiting in pregnancy have any lower vitamin
B6 nutritional status than others (Schuster et al. 1985).
Leathem (1986) stated that vitamin B6 is considered safe
for use in pregnancy, but noted that its efficacy in treating
nausea and vomiting had not been established. Two studies
give some evidence of efficacy. Sahakian et al. (1991)
conducted a double-blind trial of vitamin B6 (25 mg every
8 h for 3 d); they reported a significant reduction in vomit-
ing, and an improvement in nausea in those who initially
reported severe nausea. By contrast, Vutyavanich et al.
(1995) reported that in their trial (30 mg/d for 5 d) there
was a significant decrease in nausea, with a non-significant
trend indicating a reduction in vomiting. They noted that as
morning sickness is a self-limiting condition, it is difficult to
perform well-controlled trials.
Carpal tunnel syndrome
Carpal tunnel syndrome (compression of the median nerve
as it passes through the carpal tunnel, the space between the
bones of the wrist and the connective tissue over the flexor
tendons) is a major source of occupational health problems.
A number of studies have suggested that inadequate vitamin
B6 status is an aetiological factor or that supplements may
relieve the condition, although there is no physiological
reason to expect vitamin B6 to have any effect on the
aetiology or progression of the condition. The early work
in this area, and indeed most of the reports of a beneficial
effect of vitamin B6, have come from Ellis and coworkers
(e.g. Ellis et al. 1976, 1977, 1982; Ellis, 1987; Ellis &
Folkers, 1990). These studies suggest that vitamin B6 defi-
ciency, as assessed by erythrocyte aspartate aminotransferase
(EC 2.6.1.1.) activity, is associated with carpal tunnel syn-
drome, and responds only slowly to administration of doses of
100–200 mg vitamin B6 /d. Ellis (1987) reported that 100–
200 mg vitamin B6 /d for 12 weeks proved curative for ‘a large
proportion’ of his patients with carpal tunnel syndrome.
Smith et al. (1984) found no evidence of inadequate
vitamin B6 status in a small group of patients with carpal
tunnel syndrome, and noted that although four out of six
patients treated with vitamin B6 reported some partial
symptomatic relief, there was no consistent improvement
in clinical findings or neurophysiological measurements.
Amadio (1987) reviewed a number of studies and con-
cluded that vitamin B6 deficiency was probably not asso-
ciated with occupational carpal tunnel syndrome. He also
noted that all studies published at that time were flawed by
the lack of scientific design. Franzblau et al. (1996) inves-
tigated 125 randomly selected workers, and found that
vitamin B6 status was unrelated to either self-reported
symptoms compatible with carpal tunnel syndrome or
electrophysiological measurement of nerve function.
Stransky et al. (1989) reported that in a double-blind
controlled study vitamin B6 had no advantage over placebo
or no treatment at all. Spooner et al. (1993) performed a
randomized prospective trial of vitamin B6 or placebo, and
showed that there were no differences in electrophysiologi-
cal signs, clinical signs or symptoms between the two
groups. Bernstein & Dinesen (1993) similarly showed no
effect of vitamin B6 on electrophysiological measurements,
although they did report a significant improvement in pain
scores.
Thus it appears that while there is some suggestion of
symptomatic relief in open trials, there is no evidence from
double-blind placebo-controlled trials that vitamin B6 is
effective in treating carpal tunnel syndrome.
Hypertension
Dakshinamurti & Lal (1992) have shown that vitamin B6
depletion leads to the development of hypertension in
experimental animals, which is normalized within 24 h by
repletion with the vitamin. They have proposed three
mechanisms to account for this:
(a) Central effects on blood pressure regulation as a result
of decreased synthesis of brain g-aminobutyric acid and
serotonin (5-hydroxytryptamine). Glutamate decarbox-
ylase (EC 4.1.1.15) activity in the nervous system is
especially sensitive to vitamin B6 depletion (Bayoumi
et al. 1972), possibly as a result of mechanism-depen-
dent inactivation by transamination (Meister, 1990).
There is no evidence that aromatic amino acid decar-
boxylase activity is reduced in vitamin B6 deficiency
(Eberle & Eiduson, 1968; Eiduson et al. 1972), but there
is reduced formation of serotonin in the central nervous
system (Dakshinamurti et al. 1976).
(b) Increased sympathetic nervous system activity. There is
evidence of elevated plasma concentrations of adrena-
line and noradrenaline in vitamin B6-deficient animals
(Paulose et al. 1988).
(c) Increased uptake of Ca by arterial smooth muscle,
leading to increased muscle tone, and hence increased
circulatory resistance and blood pressure. This could
reflect increased sensitivity of vascular smooth muscle
to calcitriol (vitamin D) action in vitamin B6 deficiency;
the membrane Ca-binding protein is regulated by vitamin
D and vascular tissue has calcitriol receptors (Viswanathan
et al. 1991; Lal & Dakshinamurti, 1993, 1995).
In addition to these mechanisms (which are not mutually
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exclusive), it is likely that vitamin B6 deficiency will result
in increased end-organ responsiveness to glucocorticoids,
mineralocorticoids and aldosterone; over-secretion of (and
presumably also enhanced sensitivity to) any of these
hormones can result in hypertension. Vitamin B6 supple-
mentation would be expected to reduce end-organ sensitiv-
ity to these hormones, and thus might have a hypotensive
action. Fregly & Cade (1995) showed that supplements of
300 mg vitamin B6/kg body weight per d attenuated the
hypertensive response of rats treated with deoxycorticoster-
one acetate. At a more realistic level of supplementation
(five times the usual amount provided in the diet), Lal et al.
(1996) showed that vitamin B6 prevented the development
of hypertension in the Zucker (fa/fa) obese rat. Withdrawal
of the vitamin supplement led to the development of
hypertension. Ayback et al. (1995) showed that supplements
of 5 mg/kg body weight per d led to reduced blood pressure
in patients with essential hypertension.
Drug interactions with vitamin B6
The antituberculosis drug isoniazid (iso-nicotinic acid
hydrazide) reacts non-enzymically with PLP to form a
metabolically inactive hydrazone, resulting in functional
vitamin B6 deficiency (Vilter, 1964; Standal et al. 1974).
This is most commonly seen as secondary pellagra, due to
impaired activity of kynureninase (see Fig. 2), and hence
impaired synthesis of nicotinamide nucleotides from tryp-
tophan. The pellagra responds to supplements of vitamin B6
(Biehl & Vilter, 1954). Isoniazid also leads to the develop-
ment of peripheral neuropathy, which also responds to
vitamin B6 supplements (Gammon et al. 1953). This has
led to the belief that vitamin B6 deficiency causes peripheral
neuropathy (Jones & Jones, 1963), although there is no
evidence of this. The neuropathy seems to be an effect of
isoniazid intoxication; the response to vitamin B6 is the
result of removing isoniazid as the pyridoxal adduct, rather
than repleting vitamin B6-deficient tissues (Snider, 1980).
When relatively high doses of isoniazid were used to
treat tuberculosis, it was common to give vitamin B6
supplements; this had no effect on the therapeutic action
of the drug, but did prevent the peripheral neuropathy and
secondary pellagra (Biehl & Vilter, 1954). When lower
doses of isoniazid were introduced, in a therapeutic cocktail
with other medication, vitamin B6 supplementation became
less usual. However, cases of isoniazid-induced pellagra
have been reported among people taking low doses of
isoniazid; it is likely that many of those affected were
genetically slow acetylators of isoniazid, so that a low
dose was, for them, equivalent to a higher dose for a fast
acetylator (Bender & Russell-Jones, 1979). There have been
a number of reports of successful treatment of acute
isoniazid intoxication with vitamin B6 supplements
(Brent et al. 1990; Alvarez & Guntapalli, 1995; Shah et
al. 1995).
Other hydrazine derivatives can also cause vitamin B6
depletion by forming hydrazones, leading to the develop-
ment of secondary pellagra; these include the anti-
Parkinsonian drugs Benserazide and Carbidopa (Bender
et al. 1979; Bender, 1980a,b).
When dopa was first introduced for the treatment of
Parkinsonism, one of the most frequent side-effects was
persistent nausea and vomiting. Because of the (slight)
evidence that vitamin B6 has an anti-emetic and anti-
nauseant action, supplements were given together with
dopa. The result was a considerable reduction in the efficacy
of dopa in controlling Parkinsonian signs and symptoms; the
magnitude of the effect was related to the dose of pyridoxine
given (Hunter et al. 1970). The problem was due to the
formation of a stable tetrahydroisoquinoline adduct between
PLP and dopa (Evered, 1971) which not only reduced the
concentration of dopa available for uptake into the brain,
but also acted as an inhibitor of aromatic amino acid
decarboxylase (Fellman & Roth, 1971).
Theophylline therapy for asthma can cause seizures, appar-
ently as a result of reaction with PLP, leading to low plasma
concentrations, and hence reduced synthesis of g-aminobuty-
ric acid in the central nervous system. Glenn et al. (1995)
showed that the administration of vitamin B6 to mice
treated with theophylline reduced the number of seizures;
in rabbits, vitamin B6 reversed the changes in electro-
encephalogram caused by high doses of theophylline.
High doses of vitamin B6 may lower blood concentrations
of anticonvulsant medication such as phenytoin and pheno-
barbitone, apparently by increasing the rate of metabolism
of the drugs (Hansson & Sillanppaa, 1976).
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Fig. 2. Tryptophan metabolism. Tryptophan dioxygenase, EC
1.13.11.11; formylkynurenine formamidase, EC 3.5.1.9; kynurenine
hydroxylase, EC 1.14.13.9; kynureninase, EC 3.7.1.3; kynurenine
aminotransferase, EC 2.6.1.7 and EC 2.6.1.63.
Toxicity of vitamin B6
Animal studies have shown that vitamin B6 is potentially
neurotoxic, causing peripheral neuropathy, with ataxia,
muscle weakness and loss of balance in dogs given
200 mg pyridoxine/kg body weight for 40–75 d (Phillips
et al. 1978), and the development of a swaying gait and
ataxia within 9 d at a dose of 300 mg/kg body weight
(Krinke et al. 1980). At the lower dose of 50 mg/kg body
weight there are no clinical signs of toxicity, but histologi-
cally there is loss of myelin in dorsal nerve roots. At higher
doses there is widespread neuronal damage, with loss of
myelin and degeneration of sensory fibres in peripheral
nerves, the dorsal columns of the spinal cord and the
descending tract of the trigeminal nerve. The clinical
signs of toxicity after 200–300 mg vitamin B6 /kg body
weight regress within 3 months after the withdrawal of
these massive doses, but sensory nerve conduction velocity,
which decreases during the development of the neuropathy,
does not recover fully (Schaeppi & Krinke, 1982).
At even higher doses (500 or 1000 mg/kg body weight by
intraperitoneal injection) pyridoxine has been shown to
cause a decrease in testis weight, histological changes in
the testes and reduced spermatogenesis and sperm motility
(Mori et al. 1992; Tsutsumi et al. 1995). The relevance of
this, in terms of either the route of administration or the
massive doses involved, to high oral intakes of the vitamin
in human beings is doubtful.
Schaumburg et al. (1983) reported the development of
sensory neuropathy in seven patients who had been taking
between 2 and 7 g pyridoxine/d for several months (for a
variety of reasons). On withdrawal of the vitamin supple-
ments there was considerable recovery of neuronal function,
although there was some residual nerve damage in some
patients. In a later study, the same authors (Berger et al.
1992) gave 1 or 3 g vitamin B6 /d to healthy volunteers, and
assessed both clinical signs and symptoms of sensory
neuropathy and also quantitative sensory thresholds and
other neurophysiology. Electrophysiological and clinical
abnormalities developed at the same time, and developed
sooner in subjects receiving the higher dose of the vitamin.
Symptoms continued to progress for 2–3 weeks after
cessation of the supplements before regressing, although
plasma concentrations of PLP had returned to normal.
McLachlan & Brown (1995) reported the development of
sensory neuropathy within 2 years of starting daily admin-
istration of 2000 mg/d to an infant with vitamin B6-depen-
dent seizures, but noted that over the following 16 years the
neuropathy did not progress. However, most reports of
patients with vitamin B6 dependency diseases do not men-
tion sensory neuropathy. Mpofu et al. (1991) reported
electrophysiological and neurological examination of
seventeen homocystinuric patients who had been treated
with 200–500 mg vitamin B6 /d for 10–24 years; they found
no evidence of neuropathy.
None of the studies in which there has been objective
neurological examination has shown any evidence of sen-
sory nerve damage at intakes of vitamin B6 below 200 mg/d,
and most have shown adverse effects only at considerably
higher levels of intake.
One study suggests that relatively modest doses of
vitamin B6 may cause sensory nerve damage. Dalton &
Dalton (1987) specifically asked patients who were taking
50–100 mg vitamin B6 /d for premenstrual syndrome to
report symptoms such as tingling in the fingers, which
might be interpreted as evidence of sensory neuropathy; a
significant number of women taking 50 mg/d reported such
symptoms. However, there was no neurological examina-
tion of any of the subjects, and no patients with similar
premenstrual symptoms but not taking vitamin B6 were
asked the same questions. By contrast, Brush et al. (1988)
conducted a retrospective examination of the records of
630 women who had received 40–200 mg vitamin B6 for
treatment of premenstrual syndrome, and noted that
no symptoms were reported that suggested peripheral
neuropathy.
The mechanism of nerve damage caused by vitamin B6
supplements is not known. It is likely that PLP itself is
responsible. In patients with hypophosphatasia (lack of
plasma alkaline phosphatase (EC 3.1.3.1)), plasma concen-
trations of PLP are very considerably higher than normal,
even at normal intakes of the vitamin (Whyte et al. 1985).
However, the On-line Mendelian Inheritance in Man data-
base (http://www3.ncbi.nlm.nih.gov/Omim/) lists seizures
as the only neurological sign in the (autosomal recessive)
infant and childhood forms of the disease, and no neuro-
logical signs at all in the (autosomal recessive) infant form
of the disease. Furthermore, plasma concentrations of PLP
do not rise above about 1000 nmol/l (10–15-fold higher than
normal) even at very high levels of intake of the vitamin.
However, plasma concentrations of pyridoxal and 4-pyri-
doxic acid do continue to increase with increasing intakes of
the vitamin (Coburn et al. 1983). Schaeffer et al. (1995)
similarly showed that while plasma concentrations of pyr-
idoxal and 4-pyridoxic acid increased significantly in rats
fed up to 250 times the normal of 7 mg pyridoxine/kg diet,
for 10 weeks, PLP did not increase. There was no change in
the concentration of B6 vitamers in muscle, liver, kidney or
brain, and no evidence of overt toxicity.
Cheng & Mudge (personal communication) have found
that Schwann cells in culture grow less well when provided
with pyridoxal in the culture medium than when the vitamin
B6 source is pyridoxine. Indeed, in their hands the addition
of pyridoxal to the culture medium decreased cell survival
even in the presence of an adequate concentration of
pyridoxine. This suggests a possible neurotoxic action of
pyridoxal. It is not known whether pyridoxal is similarly
cytotoxic to other cell types in culture, although they stated
that other research groups had observed improved survival
of various cells in culture when pyridoxine rather than
pyridoxal was added to the culture medium.
While there is no doubt that vitamin B6 is neurotoxic in
gross excess, there is considerable controversy over the way
in which toxicological data have been translated into limits
on the amounts that may be sold freely as ‘nutritional
supplements’. This appears to have been achieved by the
application of standard toxicology safety margins, and
taking as the upper safe limit of intake 1% of the ‘no
adverse effect level’. While this is appropriate for setting
limits on additives and contaminants, it can be argued that it
is not appropriate as a basis for setting limits on a nutrient;
indeed for many nutrients an upper limit of intake
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established in this way would be below the average require-
ment to prevent deficiency. There is little evidence, apart
from the report of Dalton & Dalton (1987) of an uncon-
trolled study, that intakes of up to 200 mg (Bernstein, 1990)
or 500 mg (Cohen & Bendich, 1986) vitamin B6 /d for
prolonged periods, are associated with any adverse effects;
clinical signs of neuropathy are associated with higher
levels of intake, typically in excess of 1000 mg/d.
There is little convincing evidence that supplements of
vitamin B6 above levels to prevent deficiency have any
beneficial effects, although a considerable number of
women report or believe that supplements relieve the
symptoms of the premenstrual syndrome. Equally, there is
little convincing evidence that the levels of intake that are
suggested or believed to be beneficial in treating the
premenstrual syndrome are associated with any significant
toxic hazard.
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